晚期非小细胞肺癌患者TKI靶向治疗与肿瘤组织EGFR基因突变的关系

The relationship between TKI targeting therapy and EGFR gene mutation in patients with advanced non-small cell lung cancer

目的探讨晚期非小细胞肺癌(NSCLC)患者酪氨酸激酶抑制剂(TKI)靶向治疗与肿瘤组织表皮生长因子(EGFR)基因突变的关系。方法回顾性分析广元市中心医院2015年1月～2017年1月180例接受TKI靶向治疗的NSCLC患者的临床资料,所有患者均经病理证实为NSCLC,治疗前对所有患者血浆样本EGFR突变进行检测,然后接受TKI靶向治疗。分析EGFR突变与患者一般资料的关系,并探讨EGFR突变对TKI靶向治疗效果及预后的影响。结果 180例NSCLC患者中,118例为野生型,62例为突变型,突变率为34.44%。性别、无吸烟史、组织学类型与EGFR突变有关(P <0.05);其余一般资料与EGFR突变无关(P> 0.05)。EGFR突变患者有效率高于EGFR野生型患者,差异有统计学意义(P <0.05)。EGFR突变型患者1年生存率高于EGFR野生型,差异有统计学意义(P <0.05)。结论 NSCLC患者EGFR基因突变与性别、无吸烟史、组织学类型有关,EGFR突变型患者接受TKI靶向治疗的效果较好,有利于提高患者1年生存率。

Objective To investigate the relationship between tyrosine kinase inhibitor (TKI) targeting therapy and epithelial growth factor receptor (EGFR) gene mutation in patients with advanced non-small cell lung cancer (NSCLC). Methods The clinical data of 180 patients with NSCLC who received TKI targeted therapy from January 2015 to January 2017 in Guangyuan Center Hospital were retrospectively analyzed. All patients were pathologically confirmed as NSCLC, on all plasma samples from patients with EGFR mutation were detected before treatment, and then received TKI targeted therapy. The relationship between EGFR mutation and patient baseline data was analyzed, and the effect of EGFR mutation on the therapeutic effect of TKI targeted therapy and prognosis were discussed. Results A total of the 180 NSCLC patients, 118 were wild type and 62 were mutant, and the mutation rate was 34.44%. Sex, no smoking history, histology type were related to EGFR mutation (P < 0.05);the other baseline data were not related to EGFR mutation (P > 0.05). The EGFR mutant was higher than that of the EGFR wild type, and the difference was statistically significant (P < 0.05). The 1 year survival rate of EGFR mutant patients was higher than that of EGFR wild type, and the difference was statistically significant (P < 0.05). Conclusion The EGFR gene mutation in NSCLC patients is related to gender, no smoking history and histological type. EGFR mutant patients receiving TKI targeted therapy is better, which is beneficial to improve the 1 year survival rate of patients.